Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Comparative evaluation of ipss-m and cpss-mol in CMML: Impact of molecular markers on prognosis

View Full Paper
Ask AI
Bookmark
Share

Authors

YOYotaro OchiLSLaurenz SteinerVRVladimir Riabov

Discussion

Loading...

Member takes

Overview

Retrospective analysis highlights molecular markers influence prognosis in CMML, suggesting genetic profiling improves risk assessment.

Key Points

  • RUNX1 mutations significantly increase risk of poor outcomes in CMML, emphasizing the need for genetic markers.
  • Kaplan-Meier estimates showed median overall survival of 9.6 months for very high-risk compared to 13.6 months for high-risk with CPSS-Mol in MP-CMML.
  • Cox regression identified low cytogenetic risk profile and specific genetic alterations as independent prognostic factors in CMML patients.
  • Incorporation of comprehensive molecular data enhances the prognostic capacity of models used for CMML classification.

Cite This Study

Ochi et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d842https://doi.org/10.1182/blood-2025-3860
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Integrated machine learning-based prognostic models for patients with Myelodysplastic Syndromes/neoplasms (MDS)2025
  2. 2Enhanced IPSS-m: A comorbidity-integrated model for improved clinical risk stratification in myelodysplastic neoplasms2025
  3. 3IPSS-m outperforms IPSS-R in younger adults with Myelodysplastic Syndromes: A retrospective age-stratified analysis2025
  4. 4Prognostic impact of pre-transplant IPSS-m risk downstaging in Myelodysplastic Syndromes2025
  5. 5Clonal evolution and risk assessment in myelodysplastic syndromes (MDS): A prospective Study of dynamic IPSS-m validation and evolutionary trajectory modeling by the italian MDS foundation (FISIM)2025